Ben Burnett

New Capabilities

Cut his price target on Rapport to $50 while keeping an Overweight rating

Rapport Therapeutics' epilepsy pill beat placebo in a mid-stage bipolar mania trial, the company said Oct. 20. The 3.1-point gap on a 60-point mania scale was statistically significant, but it missed the four points chief executive Abraham Ceesay had called clinically meaningful.

Updated Oct 26